Rchr
J-GLOBAL ID:201801004862118654   Update date: Sep. 01, 2020

Furuya Hidekazu

Furuya Hidekazu
Affiliation and department:
Papers (11):
  • Ishii S, Isozaki T, Furuya H, Takeuchi H, Tsubokura Y, Inagaki K, Kasama T. ADAM-17 is expressed on rheumatoid arthritis fibroblast-like synoviocytes and regulates proinflammatory mediator expression and monocyte adhesion. Arthritis research & therapy. 2018. 20. 1. 159
  • Airi Nishimi, Takeo Isozaki, Shinichiro Nishimi, Sho Ishii, Takahiro Tokunaga, Hidekazu Furuya, Kuninobu Wakabayashi, Tsuyoshi Kasama. Correction to: ADAM-17 is expressed in the inflammatory myopathy and is involved with interstitial lung disease (Clinical Rheumatology, (2018), 37, 4, (1017-1024), 10.1007/s10067-018-4014-5). Clinical Rheumatology. 2018. 37. 4. 1017-1024
  • Airi Nishimi, Takeo Isozaki, Shinichiro Nishimi, Sho Ishii, Takahiro Tokunaga, Hidekazu Furuya, Kuninobu Wakabayashi, Tsuyoshi Kasama. ADAM-17 is expressed in the inflammatory myopathy and is involved with interstitial lung disease. Clinical Rheumatology. 2018. 37. 4. 1025-1026
  • Yusuke Miwa, Hidekazu Furuya, Ryo Yanai, Tsuyoshi Kasama, Kenji Sanada. Is the serum oxytocin level altered by treatment in rheumatoid arthritis patients complicated with depression?. European journal of rheumatology. 2018. 5. 1. 22-26
  • Yusuke Miwa, Mayu Saito, Hidekazu Furuya, Ryo Yanai, Tsuyoshi Kasama. Predictor of the simplified disease activity index 50 (SDAI 50) at month 3 of bDMARD treatment in patients with Long-Established rheumatoid arthritis. Open Rheumatology Journal. 2017. 11. 106-112
more...
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page